Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis.

Front Cardiovasc Med · 2022 · PMC8963358 · PMID 35360018

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)

Also, upon TGF-β1 stimulation, cardiac hypertrophy associated protein phospholipase C (PLC) and epithelial cell adhesion molecule (Ep-CAM), involved in epithelial-mesenchymal transition (EMT), showed a trend toward increased expression ( p = 0.054 and p = 0.061, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.